[^1]
[^2]
[^3]
| ATG2A Protein |
|---|
| Protein Name | Autophagy-related protein 2A |
| Gene | [ATG2A](/genes/atg2a) |
| UniProt ID | [Q9Y2P5](https://www.uniprot.org/uniprot/Q9Y2P5) |
| PDB Structure | Not determined |
| Molecular Weight | ~210 kDa |
| Subcellular Localization | ER membrane, autophagosome |
| Protein Family | ATG2 family |
ATG2A Protein is a protein encoded by the ATG2A gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
ATG2A is a large peripheral membrane protein with multiple domains:
- N-terminal region: Contains a putative membrane-binding domain that interacts with the ER
- Central region: Features WD40 repeat-like beta-propeller structures
- C-terminal region: Contains the conserved ATG2 domain essential for autophagosome formation
The protein lacks transmembrane domains but associates peripherally with lipid membranes through amphipathic helices.
ATG2A plays essential roles in neuronal autophagy:
- Autophagosome formation: Acts as a scaffold protein during the initial stages of autophagosome biogenesis
- Lipid droplet metabolism: Regulates lipid droplet mobilization and distribution in neurons
- ER-to-autophagosome lipid transfer: Facilitates membrane expansion of the growing autophagosome
- Neuronal homeostasis: Maintains protein quality control in post-mitotic neurons
In the central nervous system, ATG2A is expressed in neurons and astrocytes, where it supports cellular clearance mechanisms critical for synaptic plasticity and neuronal survival.
Dysregulation of ATG2A contributes to several neurodegenerative diseases:
- Impaired autophagic flux observed in AD brains correlates with altered ATG2A expression
- Reduced ATG2A function may contribute to accumulation of amyloid-beta and damaged organelles
- Studies show ATG2A is downregulated in AD patient brains
- ATG2A variants have been associated with PD risk in genome-wide studies
- Loss of ATG2A function leads to accumulation of alpha-synuclein aggregates
- Mitophagy defects in PD models involve ATG2A dysregulation
- ATG2A mislocalization observed in ALS patient motor neurons
- Altered autophagy protein dynamics in ALS pathogenesis
- Genetic studies suggest ATG2A may modify ALS disease progression
- Autophagy defects in HD models involve ATG2A dysfunction
- Mutant huntingtin protein disrupts ATG2A-mediated autophagic processes
Current therapeutic approaches targeting ATG2A:
- Small molecule activators: No specific ATG2A activators in clinical trials yet
- Gene therapy approaches: AAV-mediated ATG2A overexpression being explored in preclinical models
- Autophagy modulators: mTOR inhibitors indirectly enhance ATG2A function
- Research tools: ATG2A-specific antibodies for biomarker development
Categories: Proteins | Autophagy Proteins | Neurodegeneration